Analysis shows raised neurofilament levels in Parkinson's Disease patients with A53T mutation, suggesting utility in clinical trials.
A53T-PD patients have high NfL levels, which could potentially be used as an outcome in clinical trials with disease-modifying agents. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
No takes yet. Share an insight, caveat, or question.
Papagiannakis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: